Terms: = Ovarian cancer AND FOXP1, MGC12942, 27086, ENSG00000114861, hFKH1B, MGC99551, FLJ23741, QRF1, 12CC4, HSPC215, MGC88572 AND Prognosis
5 results:
1. Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
Ricci F; Fratelli M; Guffanti F; Porcu L; Spriano F; Dell'Anna T; Fruscio R; Damia G
Oncotarget; 2017 Jan; 8(5):7441-7451. PubMed ID: 26910918
[TBL] [Abstract] [Full Text] [Related]
2. Expression of foxp1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis.
Hu Z; Zhu L; Gao J; Cai M; Tan M; Liu J; Lin B
Tumour Biol; 2015 Sep; 36(9):7269-75. PubMed ID: 25895457
[TBL] [Abstract] [Full Text] [Related]
3. Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel.
Cicek MS; Koestler DC; Fridley BL; Kalli KR; Armasu SM; Larson MC; Wang C; Winham SJ; Vierkant RA; Rider DN; Block MS; Klotzle B; Konecny G; Winterhoff BJ; Hamidi H; Shridhar V; Fan JB; Visscher DW; Olson JE; Hartmann LC; Bibikova M; Chien J; Cunningham JM; Goode EL
Hum Mol Genet; 2013 Aug; 22(15):3038-47. PubMed ID: 23571109
[TBL] [Abstract] [Full Text] [Related]
4. NotI microarrays: novel epigenetic markers for early detection and prognosis of high grade serous ovarian cancer.
Kashuba V; Dmitriev AA; Krasnov GS; Pavlova T; Ignatjev I; Gordiyuk VV; Gerashchenko AV; Braga EA; Yenamandra SP; Lerman M; Senchenko VN; Zabarovsky E
Int J Mol Sci; 2012 Oct; 13(10):13352-77. PubMed ID: 23202957
[TBL] [Abstract] [Full Text] [Related]
5. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.
Kim YS; Hwan JD; Bae S; Bae DH; Shick WA
BMC Cancer; 2010 Oct; 10():576. PubMed ID: 20969748
[TBL] [Abstract] [Full Text] [Related]
